Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Actinium Pharmaceuticals (ATNM) EBITDA Margin (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed EBITDA Margin for 4 consecutive years, with 6324.44% as the latest value for Q3 2025.

  • Quarterly EBITDA Margin changed N/A to 6324.44% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 34960.0% through Dec 2025, changed N/A year-over-year, with the annual reading at 40274.44% for FY2025, N/A changed from the prior year.
  • EBITDA Margin for Q3 2025 was 6324.44% at Actinium Pharmaceuticals, up from 21775.56% in the prior quarter.
  • The five-year high for EBITDA Margin was 549.36% in Q1 2022, with the low at 34991.3% in Q4 2021.
  • Average EBITDA Margin over 3 years is 10829.13%, with a median of 4550.42% recorded in 2025.
  • Peak annual rise in EBITDA Margin hit 31430bps in 2022, while the deepest fall reached -1899916bps in 2022.
  • Over 3 years, EBITDA Margin stood at 34991.3% in 2021, then surged by 38bps to 21775.56% in 2022, then surged by 71bps to 6324.44% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 6324.44%, 21775.56%, and 17444.44% for Q3 2025, Q3 2022, and Q2 2022 respectively.